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INTRODUCTION
Cardiovascular disease (CVD) is the top 
cause of death globally;1 it causes a third 
of deaths worldwide2 and is projected to 
remain the single leading cause of death.3 
To help identify individuals at increased 
risk of it, many clinicians use risk-
assessment tools, such as those using 
the Joint British Societies’ (JBS2) and 
QRISK2 tools.4,5 The former is based on the 
Framingham algorithm to give a probability 
of developing a cardiovascular event within 
the next 10 years, and gives GPs a basis and 
rationale on which to prescribe medication 
to reduce overall CVD risk.6–8 The JBS2 
tool and a few other cardiovascular risk 
assessment tools take account of a family 
history of premature CHD as a proxy for 
genetic predisposition.4,5,7,9 
Recent genome studies have identified 
genetic variants, such as the 9p21 gene, 
as strong independent risk factors for 
CHD. This information may have clinical 
utility in reclassifying CHD risk.10–12 At the 
same time, predictive genetic tests are 
increasingly being offered commercially, 
directly to consumers over the counter.13 
The current limitations of this type of 
genetic testing are not always considered, 
with both participants and clinicians not 
fully understanding the test results.14,15 This 
may lead either to false reassurance or 
unnecessary increased stress or anxiety.14 
However, using genetic testing in primary 
care could be useful as a tool to encourage 
risk-reducing behaviour in those at risk 
of developing CVD.16–18 Arguably, this may 
be more effective than conventional 
cardiovascular risk assessment alone, as 
genetic risk may seem more personal and 
salient than family history.19 
In this study, adults who had had a recent 
cardiovascular risk assessment in general 
practice were offered a genetic test for CHD 
to explore the acceptability and feasibility 
of the procedure and assessment. This 
article reports a qualitative exploration with 
participants on how they made sense of 
the additional information from genetic 
testing and their perceptions of whether 
this influenced their behaviour. 
METHOD
Design
This qualitative interview study formed 
part of a wider mixed-methods study to 
evaluate the feasibility and clinical utility 
of genetic testing as part of conventional 
cardiovascular risk assessment. 
Participants
The consenting participants came from 
12 practices in Nottinghamshire from 
both urban and rural settings and had 
had a conventional cardiovascular risk 
assessment within the last 18 months.5 
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Abstract
Background
While primary care systematically offers 
conventional cardiovascular risk assessment, 
genetic tests for coronary heart disease (CHD) are 
increasingly commercially available to patients. It 
is unclear how individuals may respond to these 
new sources of risk information. 
Aim
To explore how patients who have had a recent 
conventional cardiovascular risk assessment, 
perceive additional information from genetic 
testing for CHD.  
Design and setting
Qualitative interview study in 12 practices in 
Nottinghamshire from both urban and rural 
settings.
Method
Interviews were conducted with 29 adults, who 
consented to genetic testing after having had a 
conventional cardiovascular risk assessment. 
Results
Individuals’ principal motivation for genetic 
testing was their family history of CHD and a 
desire to convey the results to their children. 
After testing, however, there was limited recall 
of genetic test results and scepticism about the 
value of informing their children. Participants 
dealt with conflicting findings from the 
genetic test, family history, and conventional 
assessment by either focusing on genetic risk 
or environmental lifestyle factors. In some 
participants, genetic test results appeared to 
reinforce healthy behaviour but others were 
falsely reassured, despite having an 'above-
average' conventional cardiovascular risk 
score.
Conclusion
Although genetic testing was acceptable, 
participants were unclear how to interpret 
genetic risk results. To facilitate healthy 
behaviour, health professionals should explore 
patients’ understanding of genetic test results 
in light of their family history and conventional 
risk assessment.
Keywords
coronary heart disease; family practice; genetic 
testing; primary health care.
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They were individuals who had, previously, 
received their conventional cardiovascular 
risk assessment and had chosen to have a 
genetic test, as well as agreeing to a follow-
up interview. The interviews were carried 
out 4 months after patients received their 
risk status. On recruitment, the study pack 
included a family-history questionnaire 
enquiring about CHD in first- and second-
degree relatives. 
The CHD genetic test (which is 
commercially available) involved collecting 
a saliva sample from the participant and 
sending it for analysis to University College 
London’s cardiovascular genetic laboratory. 
It comprised a cardiovascular panel of nine 
risk alleles to produce a combined risk 
profile score. 
Participants were sent a letter outlining 
the results of their conventional risk 
assessment, genetic test, and their overall 
cardiovascular risk. The letter presented both 
the conventional assessment and genetic test 
results in terms of average and above-average 
risk. In line with other risk-assessment tools, 
these were classified as follows:
• average risk; at or near population risk; 
and
• above-average; greater than population 
risk.
In the conventional cardiovascular risk 
assessment, average was <10% risk of 
developing CVD in the next 10 years and 
above average was ≥10% risk.4,5
To avoid the study interfering with 
participants’ adherence to current CVD 
risk-assessment recommendations,5 
if the conventional cardiovascular risk 
assessment suggested above-average risk 
and the genetic test indicated that risk was 
average, participants were advised that 
they were still at above-average risk of 
developing CVD.
Interview schedule
Participants were asked about their: 
• conventional risk assessment, which had 
been undertaken at the practice; 
• experience of the genetic test; and 
• interpretations and perceptions of the 
results of both assessments. 
Their views on whether results had or 
had not influenced any change in their 
behaviours over the 4 months of the study 
were also explored. 
Analytical approach
All interviews were transcribed verbatim. 
Interview data were managed using Atlas.
ti (version 5). Thematic analysis was used,20 
and codes and themes developed iteratively 
as data were analysed.21 Codes were both 
deductive (derived from the interview 
schedule) and inductive (data driven). 
RESULTS
A total of 320 individuals who had had a 
conventional CVD risk assessment were 
offered genetic testing. Of those, 119 
agreed to have the test and 30 consented 
to be interviewed; one potential participant 
was excluded from the interview because of 
psychosocial reasons. 
Table 1 outlines the participants' 
characteristics for both the main feasibility 
study and this qualitative study. Like the 
main study, most participants were males 
in their mid-50s to mid-60s, while in the 
qualitative study 41% had qualifications 
equivalent to, or greater than, A-levels. 
Of the 29 participants, seven had genetic 
test results that showed above-average 
risk, with four of these reporting a family 
history of CHD. The genetic test results 
of the remaining 22 participants showed 
they were at average risk; 13 of these had 
recalled a family history of CHD.
The age range of the 119 participants in the 
main feasibility study and the 29 interviewees 
was similar (median 59 years; interquartile 
range [IQR] 53–62 years). Proportionally, 
more males (72.4% versus 58.0%) and 
more individuals who were educated to 
undergraduate degree level (34.5% versus 
18.5%) participated in the interviews. 
In terms of being categorised differently in 
the conventional assessment and the genetic 
test, when compared with all the study 
participants, more from the qualitative study 
How this fits in
Cardiovascular risk assessment using 
conventional risk factors is routine in 
primary care but ‘direct-to-consumer’ 
genetic testing for coronary heart disease 
(CHD) is now easily available, particularly 
online. This study indicates that uptake of 
genetic testing for CHD may be particularly 
attractive to patients with a family history 
of the condition. When encountering 
individuals who have had genetic testing, 
GPs need to explore the individual’s 
understanding of the results in light of 
their family history and the previous 
conventional risk assessment to ensure 
adherence with risk-reducing behaviour. 
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had an above-average conventional CVD risk 
assessment score and an average genetic 
test score (72.4% versus 54.6%). Further, 
proportionally less interview participants 
were categorised as having an average risk 
score on both conventional CVD assessment 
and CHD genetic test (3.4% versus 26.1%).
Five main themes emerged:
• motivation to have genetic testing;
• recall and initial reaction to conventional 
risk assessment and genetic test results;
• reconciling conflicting information;
• responses to genetic test result; and
• future role of genetic testing.
Motivation to have genetic testing
Family history. The predominant motivation 
for participants accepting an offer of genetic 
testing was a family history that they wished 
to clarify further. For some, this related to a 
specific relationship – for example a parent 
or sibling with CHD – whereas, for others, 
it concerned relatives scattered across 
several generations. 
Anxiety about premature death due to 
family history was expressed by only a 
minority of participants, with some saying 
this subsided when they had passed the age 
of their relative’s death:
‘Well my father died aged 49 with coronary 
heart, you know, coronary thrombosis, so 
I just assumed there might be something 
in the family, something genetic and it was 
very difficult when I reached that age … I 
was thinking, you know, “is this my time 
up?” But obviously it wasn’t thankfully.’ 
(Participant 12, male, 62 years, above-
average CVD assessment result, average 
genetic test result, CHD family history, 
educated to degree level)
‘… and my grandfather on his side was, 
er, suffered with heart problems … which 
really made me think if I don’t look after 
what is going off, I need to be sort of sure 
of what is happening and, if it is going to 
be genetic, then it’s going to come my 
way.’ (Participant 24, male, 63 years, above-
average CVD assessment result, average 
genetic test result, CHD family history, 
educated to degree level)
Benefit to children. Responders also 
reported being tested to be able to 
discuss the outcome with their children. 
They felt the results would be useful for 
their offspring, who could make informed 
decisions if it was felt they should consider 
ways to reduce their own risk of developing 
CHD in the future:
‘The reason I was interested ... was because 
my dad died in 1989 ... I believe it was the 
cardiovascular but I don’t know. He was 62. 
It’s young isn’t it? So, obviously, I have got 
children of my own and so I need to make 
sure that it’s not something that I am likely 
to pass on or have already passed on ... So 
all I am interested in, in reality, is protecting 
my kids and myself. And I think through 
this genetic thing we should be able to do 
it hopefully.’ (Participant 4, male, 57 years, 
above-average CVD assessment result, 
average genetic test result, CHD family 
history, educated to vocational level)
However, at interview, very few 
participants had made their children aware 
of the genetic test. Although children were 
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Table 1. Participants’ characteristics
 Feasibility study, Qualitative study,  
 n = 119 (%)a subsample, n = 29 (%)a
Excluded participants 1 (0.84) 0
Age in years, median (IQR) 59 (53–62) 59 (53.5–62)
Male sex 69 (58.0) 21 (72.4)
Ethnic group  
White 96 (80.7) 28 (96.6) 
Asian 1 (0.8) 0 (0.0) 
Mediterranean 1 (0.8) 1 (3.4) 
Missing 21 (17.6) 0 (0.0)
Educational/professional qualification 
GCSE/O-level/CSE 14 (11.8) 2 (6.9) 
Vocational qualification 6 (5.0) 3 (10.3) 
A-level or equivalent 14 (11.8) 2 (6.9) 
First degree 22 (18.5) 10 (34.5) 
Other 21 (17.6) 5 (17.2) 
No formal qualifications 17 (14.3) 6 (20.7) 
Still studying 1 (0.8) 0 (0.0) 
Missing 24 (20.2) 1 (3.4)
CVD risk score 
Average risk (<10%, 10-year CVD risk) 40 (33.6) 6 (20.7) 
Moderate risk (10–19% 10-year CVD risk) 53 (44.5) 18 (62.1) 
High risk (20%+, 10-year CVD risk) 26 (21.8) 5 (17.2)
CVD risk assessment/genetic test
CVD risk assessment above average  
with average genetic test  21 (72.4)
CVD risk assessment average but  
genetic test above-average  5 (17.2)
CVD risk assessment above average,  
with above-average genetic test  2 (6.9)
CVD risk assessment average with  
average genetic test  1 (3.4)
aUnless specified. CSE = Certificate of Secondary Education. CHD = coronary heart disease. CVD = 
cardiovascular disease. GCSE = General Certificate of Secondary Education. IQR = interquartile range. 
often adults, participants still felt they were 
not old enough to be concerned about CHD, 
or genetic testing:
'Erm they [adult children] haven’t shown 
particular concern [...] no I think they all 
feel they are fairly healthy.' (Participant 12, 
male, 62 years, above-average CVD risk 
assessment result, average genetic test 
result, CHD family history, educated to 
degree level)
‘No, no, no, no, you know they are 34 and 32. 
They are not, sort of… no never mentioned 
anything.’ (Participant 1, male, 65 years, 
above-average CVD assessment result, 
average genetic test result, CHD family 
history, educated to degree level)
Recall and initial reaction 
A number of participants could not initially 
recall receiving the genetic test and/or the 
cardiovascular risk assessment results, or 
what these had indicated: 
‘I may be wrong but I can’t remember ever 
having anything back.’ (Participant 25, male, 
54 years, above-average CVD assessment 
result, average genetic test result, CHD 
family history, no formal qualifications)
Some had to be reminded of the test results 
during interview. Upon receiving their 
results, some participants were confused 
by the ‘average’ and ‘above-average’ 
categories used to describe their risk. They 
had assumed there were further categories 
of increasing risk, beyond the dichotomous 
categorisation of ‘average’ and ‘above 
average’, to which they might have attached 
more importance:
‘If it had come out as ‘extremely high’ I 
would have looked at it and thought “Blimey, 
what do I need to do, what does that mean? 
Should I be ringing someone?” Erm… 
but, yes, I suppose it is half reassuring.’ 
(Participant 17, male, 36 years, average 
CVD risk assessment result, above-average 
genetic test result, CHD family history, 
educated to degree level)
Reconciling conflicting information
Some participants rationalised their 
average genetic result, whilst having a 
significant family history, by reasoning that 
the genetic test was more important than 
their reported family history of CHD:
 
'Yes, I think I was [surprised] because I was 
sure that there was something in the family 
make-up, genetic make-up, but it’s nice to 
know that it’s not the case.’ (Participant 12, 
male, 62 years, above-average CVD risk 
assessment result, average genetic test 
result, CHD family history, educated to 
degree level)
Those whose risk was classified 
as ‘average’ in the conventional risk 
assessment but above average in the 
genetic test also felt that the genetic test 
was more important:
‘I think it’s different because you don’t know 
which genes you have inherited ... so just 
because you have got family history ... It 
gives you a probability of having inherited 
that risk ... It doesn’t definitely mean you 
have, whereas if you have a genetic test 
and genetically you have that high risk …’ 
(Participant 16, female, 42 years, average 
CVD risk assessment result, above-average 
genetic test result, CHD family history, 
‘other’ education)
It was noted that family history, as well as 
identifying genetic risk factors, incorporates 
ancestors’ environmental risk factors, 
which the participant could modify or avoid:
‘ ... it seems as if I am not following in 
my ancestors’ footpath ... because if I am 
above-average [genetic risk] now, [but 
average CVD risk], whatever I have done up 
to now has been good, so let’s improve on 
it, you know. Let’s see if we can’t make that 
better.’ (Participant 19, female, 65 years, 
average CVD risk assessment result, 
above-average genetic test result, recalled 
CHD family history, ‘other’ education)
Lifestyle was seen by some responders 
as impacting on risk, independent of genetic 
inheritance, suggesting an appreciation of 
gene-environment interaction:
‘Well it’s obviously the genetics ... hasn’t 
gone down through the family and I am just 
like an everyday person but, obviously, with 
the lifestyle I have led, or lead, [it] puts me at 
greater risk than the person who didn’t live 
my lifestyle.’ (Participant 3, male, 62 years, 
above-average CVD risk assessment result, 
average genetic test result, CHD family 
history, educated to A-level standard)
Others were sceptical of the value of 
genetic testing, questioning the relevance 
of the test results to themselves and their 
offspring:
'I don't know whether these tests could 
prove positively that erm if I had got a 
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problem would my son have a problem it 
can't be proved can it ... No I don't feel that 
anything is written in stone as far as genes 
are concerned. You know it's just one of 
those things that can happen and I live 
with that.' (Participant 4, male, 57 years, 
above-average CVD risk assessment result, 
average genetic test result, CHD family 
history, educated to vocational level)
Responses to genetic test result
Behavioural change. An above-average 
result from the genetic test was, perhaps 
surprisingly, positively received by 
many participants as it confirmed their 
preconceived beliefs about familial heart 
disease risk and could push them to try to 
reduce that risk:
‘It hasn’t worried me particularly, I think 
I’ve just carried on. But it’s just given you 
another awareness really, I suppose, and, 
hopefully, try a little bit harder to do the 
right thing.’ (Participant 5, female, 61 years, 
average CVD risk assessment result, above-
average genetic test result, CHD family 
history, educated to A-level standard)
Participants expressed the benefit of 
using the result to motivate behaviour 
change, particularly when there was 
concordance between the results of the 
genetic test and the conventional risk 
assessment:
‘I think the two together, erm, the two 
bits of information just help create a 
greater incentive for me to change things.’ 
(Participant 21, male, 53 years, above-
average CVD risk assessment result, 
above-average genetic test result, no CHD 
family history, ‘other’ education)
Most participants reported already 
undertaking lifestyle risk-reducing 
behaviour, however, downplaying the fact 
that the genetic test result might influence 
their behaviour:
‘Well I don’t know what more changes 
I could make, except possibly exercising 
more, going to a gym or something like 
that. Er, I don’t know. I would if I thought I 
was living an unhealthy lifestyle. But I don’t 
think I am living an unhealthy lifestyle.’ 
(Participant 29, female, 64 years, average 
CVD risk assessment result, above-average 
genetic test result, CHD family history, 
educated to degree level)
False reassurance. In some cases, despite 
an above-average conventional risk 
assessment score, an average genetic 
test result appeared to falsely reassure 
participants that they did not have to 
modify their lifestyle, for example, so they 
remained disinclined to stop smoking. 
Similarly, an average genetic test result did 
not lead to the modification of a fatalistic 
attitude towards developing CHD. The 
individual attributed these concerns to a 
poor family history rather than increased 
risk on conventional assessment:
‘If it’s going to run in the family, you have got 
to accept it haven’t you? If it’s your turn to, if 
your number comes up, you can’t do nothing 
about it.’ (Participant 25, male, 54 years, 
above-average CVD risk assessment result, 
average genetic test result, CHD family 
history, no formal qualifications’)
It was uncommon for participants to 
describe experiencing anxiety after 
receiving their genetic test result but, 
where this was expressed, it was seen as a 
motivator to reduce risk: 
‘Well, it scares me ... Erm, well, obviously, I 
want to do everything I possibly can to avoid, 
erm, to avoid getting any heart disease.’ 
(Participant 16, female, 42 years, average 
CVD risk assessment result, above-average 
genetic test result, CHD family history, 
‘other’ education)
Future role of genetic testing
Testing using a saliva sample was 
considered to be acceptable to participants; 
none expressed concerns about the 
procedure. Some suggested this should be 
offered to the general public:
‘Er, no I think it ought to be available 
to everybody if they want to do it. Some 
people might think “I would rather not 
know”.’ (Participant 3, male, 62 years, 
above-average CVD risk assessment result, 
average genetic test result, CHD family 
history, educated to A level)
An older participant made the point that 
a genetic test was more appropriate for a 
younger age group, in whom preventative 
activities were more likely to lead to 
potential health benefits:
‘I think 25 ... At least it would point to 
them and, er, give them plenty of time to 
adjust to the lifestyle – if they want to, of 
course ...’ (Participant 3, male, 62 years, 
above-average CVD risk assessment result, 
average genetic test result, CHD family 
history, educated to A-level standard)
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Others expressed concerns about relying 
on genetic test results and said that more 
research was required to identify further 
predictive genes for CHD:
‘There will be a load of other genes that you 
don’t know about yet … I haven’t interpreted 
to mean that I haven’t got any genes 
that are involved that might increase my 
cardiovascular risk you know. I don’t take it 
to mean that it’s all environmental … I think 
there are probably other genes that will 
affect one’s cholesterol, metabolism, and 
one’s blood pressure, or whatever, that you 
perhaps haven’t mapped yet.’ (Participant 
23, female, 53 years, above-average CVD 
risk assessment result, average genetic 
test result, CHD family history, ‘other’ 
education)
A participant who had experience with 
screening for another medical condition 
highlighted concerns that genetic testing 
may lead to insurance liabilities and break 
confidentiality:
‘The only reason I took part in this genetic 
test was because it was guaranteed to 
be confidential and not passed on to any 
other party.’ (Participant 20, male, 57 years, 
average CVD risk assessment result, 
above-average genetic test result, reports 
CHD family history, educated to GCSE/O-
level/CSE level) 
DISCUSSION
Summary
The principal driver for undertaking genetic 
testing was a perceived familial risk of 
developing CHD, with participants often 
motivated by a desire to convey the results 
to their children. After testing, however, 
some participants demonstrated limited 
recall of their results and scepticism about 
the value of passing the information to their 
offspring. 
Participants had to deal with the fact 
that sometimes results from the genetic 
test, family history, and conventional 
cardiovascular risk assessment conflicted 
with each other. For some participants, 
the ways of dealing with this included 
either focusing on the genetic risk or the 
environmental lifestyle risk factors; others 
were sceptical about the value of the 
genetic test results. 
In some participants the genetic test 
results appeared to reinforce healthy 
behaviour; others were falsely reassured 
by having an average score despite their 
conventional cardiovascular risk score 
being above average. 
Participants found the testing procedure 
acceptable, and suggestions were made that 
genetic testing could lead to potential benefits 
for younger individuals by encouraging them 
to adopt risk-reducing behaviour.
Strengths and limitations 
To the study's knowledge, this is the first 
study to explore the impact of genetic 
testing in individuals who have been offered 
a CVD risk assessment in primary care. 
Previous studies have only explored the 
reactions of participants to hypothetical 
genetic testing scenarios.22
This qualitative study explored the views 
of a self-selected sample of people who 
consented to genetic testing and follow-
up interview. Although the participants 
were recruited from all of those who 
were undergoing cardiovascular risk 
assessment in a range of British general 
practices, there was limited participation 
by younger individuals, those from minority 
ethnic groups, and those from areas of 
deprivation. 
Compared with all participants in the 
main feasibility study, proportionally 
more interviewees had an above-average 
conventional assessment result and an 
average genetic test result. However, the 
views of participants with a wide range of 
conventional and genetic cardiovascular 
risk profiles were captured. 
Participants struggled to recall their 
genetic test results and had to be reminded 
of these during the interview; however, they 
were still able to give reasonable insight into 
their reaction to the results. This suggests 
that patients should be provided with more 
detailed information in the results letter. 
The study had limited opportunity to 
examine any reported impact of genetic 
testing on behavioural change as many 
participants said they had already adopted 
healthy lifestyles prior to this study being 
undertaken.
Comparison with existing literature
To the study's knowledge this is the first 
study to evaluate patients’ perspectives 
of genetic testing in the context of 
cardiovascular risk assessment in primary 
care. The majority of previous studies 
have explored the role of genetic testing 
in assessing the risk of specific monogenic 
diseases such as Huntington’s disease, 
familial hypercholesterolaemia, and, more 
generally, in genetic risk assessments for 
cancer.23–27 Participants’ opinions have 
also been ascertained in hypothetical 
scenarios.28,29
In this study, a perceived familial risk 
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of CHD was a major driver for requesting 
genetic testing. This parallels the findings in 
studies of heart disease and breast cancer 
in secondary care.30–31 Similar to this study, 
Lerman et al noted that most participants 
were motivated to know whether this 
predisposition would affect others in the 
family.31 However, the study also found that, 
after testing, some participants expressed 
scepticism about the value of passing on 
this information to their children. Further, 
participants with average genetic risk 
results found it difficult to reconcile these 
results with knowing that they had a family 
history of CHD. This is similar to the reported 
impact of a negative genetic test result for 
familial hypercholesterolaemia, which led 
to participants feeling ‘in limbo’ about their 
raised blood cholesterol.23 In this study, 
fatalism was reported in one individual only. 
This limited discussion is similar to studies 
communicating genetic test results to 
participants with a family history of familial 
hypercholesterolaemia.23,24 
Previous studies exploring the value of 
genetic testing in modifying risk-reducing 
behaviour have been disappointing. For 
those who underwent genetic testing for 
diabetes, myocardial infarction, and cancer, 
there has been little or no effect on long-
term abstinence of smoking or short-term 
changes in diet and exercise.22,28,32 
There are concerns that negative genetic 
test results for CVD may lead to false 
reassurance, while positive results may 
induce unnecessary anxiety in others.33 
In this study, the false reassurance was 
identified but not related to above-average 
results.
Implications for practice 
GPs are currently struggling to interpret 
conventional cardiovascular risk assessment 
scores and communicate the results to 
patients.34,35 Even if there was adequate 
analytical and clinical validity of these CHD 
genetic tests,36 until the fundamental issues 
of clinicians’ confidence in interpreting 
and communicating cardiovascular risk 
are resolved, incorporating genetic test 
results may be premature.35 However, 
GPs are exposed to genetic testing by 
patients presenting to discuss the results of 
commercially available (over-the-counter) 
CHD genetic tests.14 GPs will usually be 
the first point of contact and will need 
to explore the patient’s understanding of 
potentially conflicting results from genetic 
testing and conventional cardiovascular risk 
assessments. However, many clinicians 
indicate a lack of awareness on the subject 
and feel unprepared to manage such 
patients.37 
Further, in the future, genetic testing 
may be incorporated into primary care as 
a way of personalising the conventional 
cardiovascular risk assessment. In this 
instance, consideration will need to be given 
to the confidentiality of this information.15,33,38 
Although genetic testing in isolation may 
have limited utility, a high genetic risk score, 
in combination with a positive family history 
and an above-average conventional CVD 
risk assessment, may indicate a subgroup 
of the general population at particularly 
high risk of developing CVD and should be 
targeted for intensive lifestyle advice and 
lipid-lowering therapy. 
Prior to implementing further research 
on the clinical utility of CHD genetic testing, 
further exploration of the best way to 
present the results to participants should 
be undertaken, as participants in this 
study did not understand the ‘average’ and 
‘above-average’ classifications.
Any follow-up study might usefully 
involve a younger population and, as such, 
not be anchored to only those undergoing 
cardiovascular risk assessment (who 
are, in general, aged >40 years). To 
improve generalisability, future studies 
should actively recruit participants from 
various backgrounds including minority 
ethnic  communities and groups who are 
underserved. It would also be beneficial to 
follow the participants over a longer period 
of time to see whether intentions to change 
behaviours did lead to actual behavioural 
changes. 
CONCLUSION 
These results add to the existing 
knowledge about patients’ perceptions 
and understanding of their CHD risk, as 
identified by genetic testing. Participants 
had no concerns about testing procedures 
but, as they may make different judgements 
about their perceived risk of developing 
CVD in the light of their genetic risk result, 
health professionals need to explore 
patients’ understanding of the conventional 
cardiovascular risk assessment, their 
perceived family history, commercially 
available genetic tests, and the impact of 
any discrepancy between the test and risk 
assessment on risk-reducing behaviour.
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